CHICAGO--(BUSINESS WIRE)--Jeff Aronin, Chairman and CEO of Paragon Biosciences, was named 2018’s Innovator of the Year by Best in Biz Awards for his lifelong work towards developing treatments for severe medical conditions. The award recognizes Mr. Aronin’s innovation over a 25-year career and Paragon Biosciences’ success in advancing venture innovation for biopharmaceutical development under Mr. Aronin’s leadership.
The Best in Biz Awards are determined through the scoring of independent judging panels comprised of editors and reporters from respected publications and industry analysts. The 2018 panel included writers from publications such as the New York Times, Associated Press, Wired, Forbes, and the New York Post among others. The judging panels awarded Mr. Aronin Innovator of the Year at the Gold level, which is the organization's highest honor.
Mr. Aronin has received numerous awards for his approach to biopharmaceutical venture innovation. Recently, Insights Care Magazine named Mr. Aronin one of the most influential leaders in healthcare for his track record of facilitating breakthroughs in biopharmaceutical research and improving the quality of life for patients with rare conditions. Mr. Aronin leads Paragon Biosciences in its work to identify unmet patient needs, invest in the development of novel medicines, and incubate biopharmaceutical companies that work toward treatments for people with complex or rare medical conditions. In the past year, Paragon Biosciences' portfolio companies have invested and committed $454 million to the research and development of potential new medicines.
"Winning the 2018 Gold Award for Innovator of the Year is a testament to the hard work and commitment of my team at Paragon – and our vision for how to bring breakthrough therapies to patients," said Mr. Aronin. "Paragon Biosciences is focused on solving for the critical medical needs that others won't or can't address. This recognition from Best in Biz helps build awareness of our collective mission to bring novel treatments and therapies to the patients who need them most."
About Paragon Biosciences, LLC:
For severe and complex diseases, Paragon Biosciences identifies unmet patient needs, invests in novel therapies to treat those medical conditions, launches biopharmaceutical companies to further develop those therapies, and supports these new portfolio companies with early-incubation services. After which, the portfolio companies operate independently as they conduct clinical trials and seek FDA approval of improved treatments. Paragon Biosciences is headquartered in Chicago, Illinois. For more information, visit: ParagonBioSci.com.
About the Best in Biz Awards:
Since 2011, Best in Biz Awards has made its mark as the only independent business awards program judged each year by a who's who of prominent reporters and editors selected from top-tier publications from North America and around the world. Over the years, Best in Biz Awards judges have ranged from Associated Press to the Wall Street Journal and winners have spanned the spectrum, from blue-chip companies that form the bedrock of the world economy to some of the most innovative start-ups. For more information, visit: BestInBizAwards.com.